Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MP Biomedicals and Rusnano have signed an agreement of cooperation to cooperate in the areas of nanotechnology R&D to provide due conditions for production of innovative pharmaceuticals, including personal pharmacogenetic treatments.
Subscribe to our email newsletter
MP Biomedicals and Rusnano plan to jointly implement projects focused on anti-aging and increasing in life expectancy, as well as creating the infrastructure for innovations in the area of nanobiotechnology.
MP Biomedicals and Rusnano said that they have agreed to participate in the work of scientific, coordinating and other councils, expert commissions and working groups on nanobiotechnology and pharmaceutical industry, which relate to areas of the signed agreement. Both the companies have also decided to jointly provide mutual methodological and scientific-medical support for studies in the area of nanotechnology.
MP Biomedicals and Rusnano will also collaborate on creating the information infrastructure to ensure the establishment and support of databases related to scientific and medical developments, along with innovative projects in the field of biotechnology, pharmaceutical industry and nanotechnology.
MP Biomedicals and Rusnano are expected to elaborate the long-term forecast for areas of nanotechnology application in the field of life sciences, pharmaceutics and related industries with the allocation of promising emerging markets, products and services, as well as a list of priorities and critical technologies in the pharmaceutical industry.